Publications

Update on the linezolid in vitro activity through the Zyvox® Annual Appraisal of Potency and Spectrum Program (2013). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2015; 59 (4): 2454-2457

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Streit JM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 275-279

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. by Jones RN, Turnidge JD, Moeck G, Arhin FF and Mendes RE published in Antimicrob. Agents Chemother. 2015; 59 (4): 2405-2409,

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. by Flamm RK, Rhomberg P, Kaplan N, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (5): 2583-2587

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas. by Waites KB, Crabb DM, Duffy LB and Huband MD published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3627-3629

In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. by Flamm RK, Rhomberg PR, Simpson KM, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (3): 1751-1754

Surrogate Analysis of Vancomycin to Predict Susceptible Categorization of Dalbavancin, Lead author: Jones RN, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. by Kohlhoff SA, Huband MD and Hammerschlag MR published in Antimicrob. Agents Chemother. 2014; 58 (12): 7595-7596

Update on Acinetobacter species: Mechanisms of antimicrobial resistances and contemporary in vitro activity of minocycline and other treatment options. by Castanheira M, Mendes RE and Jones RN published in Clin. Infect. Dis. 2014; 59 (Suppl 6): S367-373

Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. by Mendes RE, Deshpande LM and Jones RN published in Drug Resist. Updat. 2014; 17 (1-2): 1-12

Decreased ceftriaxone susceptibility in emerging (35B, 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the USA (2011 – 2012): Ceftaroline remains active in vitro among beta-lactam agents. by Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (8): 4923-4927

In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. by Fernandez-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, Fothergill AW, Lass-Florl C and Guarro J published in Antimicrob. Agents Chemother. 2014; 58 (7): 3646-3649

In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). by Flamm RK, Jones RN and Sader HS published in J. Global Antimicrob. Res. 2014; 2 (2): 183-189

In vitro activity of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. by Pfaller MA, Messer SA, Rhomberg PR, Jones RN and Castanheira M published in J. Clin. Microbiol. 2013; 51 (8): 2608-2616

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. by VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG. published in Antimicrob. Agents Chemother. 2013; 57 (6): 2809-2814

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in Antimicrob. Agents Chemother. 2013; 57 (2): 1065-1068

In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. by He W, Kaniga K, Lynch AS, Flamm RK and Davies TA published in Diagn. Microbiol. Infect. Dis. 2012; 74 (4): 417-419

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE surveillance program (2008-2010). by Farrell DJ, Castanheira M, Mendes RE, Sader HS and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S206-S214

In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. by Farrell DJ, Krause KM and Benton BM published in Diagn. Microbiol. Infect. Dis. 2011; 69 (3): 257-279

In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler’s diarrhea and Clostridium difficile. by Farrrell DJ, Putnam SD Biedenbach DJ, Moro L, Bozzella R, Celasco G and Jones RN published in Antimicrob. Agents Chemother. 2011; 55 (3): 992-996

In vitro activity of a novel broad-spectrum antifungal, E1210, and comparators against Aspergillus spp. as determined by CLSI and EUCAST broth microdilution methods. by Pfaller MA, Castanheira M, Messer SA and Jones RN published in Antimicrob. Agents Chemother. 2011; 55 (11): 5155-5158

In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) Gram-positive organisms collected in the United States. by Jones RN, Mendes RE, Sader HS and Castanheira M published in Clin. Infect. Dis. 2011; 52 (Suppl 7): S477-S486

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. by Pfaller MA, Hata K, Jones RN, Messer SA, Moet GJ and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2011; 71 (2): 167-170

JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. by Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN published in Antimcrob. Agents Chemother. 2011; 55 (7): 3631-3634

The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). by Farrell DJ, Castanheira M, Sader HS and Jones RN published in J. Infect. 2010; 61 (6): 476-483

In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. by Farrell DJ, Robbins M, Ryhs-Williams W and Love WG published in Int. J. Antimicrob. Agents 2010; 35 (6): 531-536

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. by Biedenbach DJ, Ross JE, Putnam SD and Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (5): 2273-2275

Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007). by Sader HS, Moet GJ and Jones RN published in J. Chemother. 2009; 21 (5): 500-506

Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: Results from the DECIDE Surveillance Program (2007) by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect Dis. 2009; 64 (2): 177-184

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. by Vidaillac C, Leonard SN, Sader HS, Jones RN and Rybak MJ published in Antimicrob. Agents Chemother. 2009; 53 (6): 2360-2366

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens by Jones RN, Moet GJ, Sader HS, Mendes RE and Castanheira M published in J. Antimicrob. Chemother. 2009; 63 (4): 716-720

In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens by Jones RN, Bell JM, Sader HS, Turnidge JD and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 434-439

In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects. by Jones RN, Biedenbach DJ and Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 63 (3): 339-341

In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation. by Jones RN, Fritsche TR and Moet GJ published in Diagn. Microbiol. Infect. Dis. 2008; 61 (1): 76-79

In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate and -resistant Staphylococcus aureus. by Fritsche TR, Rhomberg PR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2008; 60 (4): 399-403

Update of the in vitro activity of daptomycin tested against 6,710 Gram-positive cocci isolated in North America (2006). by Castanheira M, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2008; 61 (2): 235-239

In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). by Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 27-32

Evaluation of the in vitro activity of daptomycin against 19,615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). by Pfaller MA, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (4): 459-465

Re-evaluation of the role of broad spectrum cephalosporins against staphylococci by applying contemporary in vitro results and pharmacokinetic/pharmacodynamic principles. by Sader HS, Bhavnani SM, Ambrose PG, Jones RN and Pfaller MA published in J. Chemother. 2007; 19 (1): 38-43

Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin structure infections. by Sader HS, Mallick R, Kuznik A, Fritsche TR and Jones RN published in Int. J. Antimicrob Agents 2007; 30 (6): 514-520

Garenoxacin activity against isolates from patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. by Jones RN, Sader HS, Stilwell MG and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 1-7

In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii. by Sader HS, Rhomberg PR and Jones, RN published in J. Chemo. 2005; 17 (6): 622-627

Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003. by Sader, H.S., Fritsche, T.R., Streit, J.M., Jones, R.N. published in J. Chemother. 2005; 17 (5): 477-483

In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. by Gales AC, Jones RN, Andrade SS, Pereira AS and Sader HS published in Braz. J. Infect. Dis. 2005; 9 (5): 348-356

Evaluation of PPI-0903M (T91825), a novel cephalosporin: Bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. by Jones RN, Fritsche TR, Ge Y, Kaniga K and Sader HS published in J. Antimicrob. Chemother. 2005; 56 (6): 1047-1052

Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multidrug resistant Pseudomonas aeruginosa and Acinetobacter spp. by Sader, H.S., Jones, R.N. published in Int. J. Antimicrob. Agents. 2005; 25 (5):380-384

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. by Fritsche TR, Kirby JT and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 49 (3): 201-209

Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). by Jones RN, Sader HS and Fristche TR published in Diagn. Microbiol. Infect. Dis. 2004; 49 (2):147-149

A pragmatic approach to identify extended-spectrum beta-lactamse-producing Klebsiella pneumoniae in Taiwan: in vitro activity of newer and established antimicrobial agents. by Yu, W-L, Chuang, Y-C, Jones, RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (4): 277-282

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 101-105